Shattuck Labs, Inc. (NASDAQ:STTK – Get Free Report) insider Arundathy Pandite sold 30,000 shares of Shattuck Labs stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $6.61, for a total value of $198,300.00. Following the sale, the insider directly owned 166,219 shares in the company, valued at approximately $1,098,707.59. This trade represents a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shattuck Labs Stock Down 1.2%
Shattuck Labs stock traded down $0.08 during trading hours on Thursday, hitting $6.67. The stock had a trading volume of 413,393 shares, compared to its average volume of 547,218. The company has a 50-day moving average of $6.61 and a two-hundred day moving average of $4.46. The company has a market cap of $511.46 million, a PE ratio of -10.59 and a beta of 1.18. Shattuck Labs, Inc. has a fifty-two week low of $0.71 and a fifty-two week high of $8.33.
Shattuck Labs (NASDAQ:STTK – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. During the same quarter in the prior year, the firm posted ($0.27) earnings per share. As a group, analysts forecast that Shattuck Labs, Inc. will post -0.51 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on STTK
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in STTK. Orbimed Advisors LLC bought a new stake in Shattuck Labs during the 3rd quarter worth about $15,072,000. NEXTBio Capital Management LP bought a new position in shares of Shattuck Labs in the fourth quarter worth about $11,497,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Shattuck Labs during the fourth quarter worth approximately $7,031,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of Shattuck Labs during the fourth quarter worth approximately $4,945,000. Finally, Bank of America Corp DE grew its stake in shares of Shattuck Labs by 2,968.2% during the third quarter. Bank of America Corp DE now owns 1,131,888 shares of the company’s stock valued at $2,705,000 after purchasing an additional 1,094,997 shares during the last quarter. 58.74% of the stock is owned by institutional investors.
Shattuck Labs Company Profile
Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.
The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.
Featured Stories
- Five stocks we like better than Shattuck Labs
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
